The autosomal recessive genetic disorder Nijmegen breakage syndrome (NBS) was first described in 1981 in patients living in Nijmegen, Holland. NBS patients display a characteristic facial appearance, microcephaly and a range of symptoms including immunodeficiency, increased cancer risk and growth retardation. In addition, NBS patient cells were found to have elevated levels of chromosomal damage and to be sensitive to ionizing irradiation (IR). This radiosensitivity had fatal consequences in some undiagnosed patients. The most dangerous DNA lesion caused by IR is considered to be the double-strand break (DSB) and indeed, NBS patient cells are sensitive to all mutagens that produce DSBs directly or indirectly. We discuss here our current understanding of how a deficiency in DSB repair manifests as the particular symptom complex of NBS.
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Chromosomal breakage and radiosensitivity
The gene responsible for Nijmegen breakage syndrome (NBS), NBS1, was identified in 1998 (Carney et al., 1998; Matsuura et al., 1998; Varon et al., 1998) , 17 years after its first description (Weemaes et al., 1981) . Over 90% of all patients analysed to date are homozygous for a 5 bp truncating mutation, 657D5 (Figure 1 ). In cell lines established from homozygotes and heterozygote carriers of the 5 bp deletion, two mutated forms of the NBS1 gene product nibrin have been observed: a 26 kDa fragment (p26-nibrin), containing the FHA and BRCT domains, corresponding to the N-terminal portion of nibrin (Figure 1) , and a 70 kDa protein (p70-nibrin), which is produced by alternative initiation of translation from a cryptic upstream start codon and represents the C-terminal portion of nibrin (Maser et al., 2001) . The existence of similar truncated proteins has been shown as a consequence of two other NBS1 mutations, 835D4 and 900D25, and is assumed for the other rare NBS1 mutations (Figure 1 ). These findings, complemented by data from knockout mice (Zhu et al., 2001) , strongly suggest that null mutations in the NBS1 gene are not compatible with viability.
Nibrin together with Mre11 and Rad50 is part of a trimeric complex (M/R/N complex) that is conserved between yeast and mammals. In response to induction of double-strand breaks (DSBs), nibrin is phosphorylated at several sites ( Figure 1 ; Gatei et al., 2000) . The kinase responsible is the primary activator of the cellular response to DSBs, ATM (ataxia telangiectasia mutated), biallelic mutation of which leads to ataxia telangiectasia (AT), a disorder with many features also found in NBS. Ionizing radiation-induced phosphorylation of nibrin is further regulated by the deacetylase SIRT1, which keeps nibrin in the hypoacetylated state necessary for efficient phosphorylation (Yuan et al., 2007) . The recently identified acetylation sites are indicated in Figure 1 . In addition, this figure shows domains of nibrin that have been assigned specific functions, for example, physical interaction with other proteins.
It has become clear in recent years that nibrin also has a role in activating autophosphorylation of ATM during the response to DNA damage (Uziel et al., 2003; Lee and Paull, 2005) . This function will be discussed in detail in other articles of this issue; however, this mutual dependency of nibrin and ATM reflects the phenotypical overlap in patients with NBS and AT in, for example, immunodeficiency.
Immunodeficiency in NBS patients
Nijmegen breakage syndrome patients have deficiencies in both cellular and humoral immune responses leaving them prone to various infections, particularly of the respiratory tract. Nibrin is not involved in V(D)J recombination (Yeo et al., 2000) ; however, we and others have shown that nibrin is involved in immunoglobulin class switching using conditional null mutant mouse models (Kracker et al., 2005; Reina-San-Martin et al., 2005) . In our hands, less than 50% of null-mutant B-lymphocytes were able to switch from expressing cell surface IgM to IgG1 or IgG3 (Kracker et al., 2005) . Interestingly, in a humanized mouse model, where human p70-nibrin compensates for the null mutation of the endogenous murine gene Nbn, lymphocyte surface Igs were normal, although serum Igs showed a reduction of IgG1 and IgG3 isotypes reminiscent of patients : over 90% of NBS patients have deficiencies of IgA or IgG, or both. Since nibrin is clearly essential for cell proliferation (Dumon-Jones et al., 2003; Demuth et al., 2004) , the cellular immunodeficiency observed in NBS patients probably reflects this aspect of nibrin's function.
The cell cycle and apoptosis in NBS patient cells
Cell cycle checkpoints have been extensively analysed in NBS cells, as one of their hallmarks is the resistance of DNA synthesis to IR. This phenomenon is attributed to a defective intra-S-phase checkpoint and is also observed in AT cells. In addition, deficient G 1 -to S-phase and G 2 to mitosis transitions have been reported for NBS cells; however, there is some controversy in the literature. These discrepancies can be explained, at least in part, by the use of different cell types and the different mutations in the human and mouse cells analysed.
The generation of mice carrying inducible Nbn null mutations has allowed the investigation of cells devoid of nibrin. We found that such Nbn null mutant fibroblasts are clearly defective in the G 2 /M checkpoint following treatment with the radiomimetic drug bleomycin (Demuth et al., 2004) . In another study, parallel analysis of B cells from mice with an induced Nbn null mutation, with or without a copy of the human NBS1 gene carrying the major NBS1 mutation 657D5, was performed. Cells null for Nbn displayed defective intra-S-phase and G 2 /M-phase checkpoint responses, which were comparable to that of ATM knockout cells. The null cells expressing p70-nibrin were less affected, a finding that was also true for other end points analysed in this work, when compared with the null cell phenotype .
A role for nibrin in the activation of ATM and in mediation of phosphorylation by ATM was suggested by attenuated phosphorylation kinetics in NBS patient cells. In agreement, Nbn null B cells treated with IR showed practically no phosphorylation of ATM at Ser1981 . Downstream phosphorylation targets of ATM were also affected, with no significant phosphorylation of Smc1, CHK2 or Brca1 in response to IR. This explains the intra-S and G 2 /M checkpoint defects in these knockout cells, which are similar in magnitude to ATM knockout cells. Interestingly, the same conditional mouse model revealed that Nbn null B cells rescued by the human NBS1 gene encoding nibrin have an intact checkpoint in response to IR, even if nibrin's own phosphorylation sites are mutated. This is in contrast to previous findings obtained on patient cells, which implicated these ATM-mediated nibrin phosphorylation events in control of the intra-Sphase checkpoint (Lim et al., 2000) . Figure 1 The NBS1 gene and its protein nibrin. The exon structure of the NBS1 gene is shown together with the sites of mutations found in Nijmegen breakage syndrome patients; the major mutation, 657D5, is in red. The full-length nibrin protein, with an apparent molecular weight of 95 kDa on sodium dodecyl sulfate gels, and the two protein fragments arising from the 657D5 mutation, p26-nibrin and p70-nibrin, are shown. The locations of serine residues targeted by the ATM kinase and acetylated lysine residues, which are deacetylated by the SIRT1 deacetylase, are indicated. The relative locations of the FHA, BRCT, Mre11-binding and ATM-interaction domains are given and other functional domains are indicated by solid lines. The protein fragments p26-nibrin and p70-nibrin are predicted to contain alternative C-terminal or N-terminal amino acids, which are indicated in purple.
Defective response to DNA DSBs I Demuth and M Digweed Nibrin's role in apoptosis is also controversial, and again, the use of cells expressing p70-nibrin with residual activity might explain the inconsistent findings. ATM is known to be involved in IR-induced apoptotic pathways, which are either p53-dependent, resulting in transcriptional activation of proapoptotic genes, or p53-independent via phosphorylation of CHK2 and E2F1 (Powers et al., 2004; Urist et al., 2004) . In the context of nibrin's role in ATM activation, it seems appropriate to imply a function for nibrin in apoptosis and this has been confirmed by recent studies on mouse models. Thymocytes from mice with a null mutation in Nbn, which have been rescued by the human NBS1 gene encoding a protein lacking the C-terminal 20 amino acids, show a reduced sensitivity to IR-induced apoptosis (Difilippantonio et al., 2007) . This apoptotic defect was accompanied by reduced p53 phosphorylation at Ser15. A severe apoptotic defect was also observed in another mouse model expressing mouse nibrin with the C-terminal 25 amino acids deleted. Interestingly, in this case, phosphorylation and stabilization of p53 was not altered, whereas ATM-mediated phosphorylation of the proapoptotic BID protein was reduced (Stracker et al., 2007) . A study on human lymphoblastoid cell lines established from the same progenitor but with different p53 status supported the view that nibrin functions in both p53-dependent and p53-independent IR-induced apoptosis via its role in activating ATM . The consequence of diminished apoptosis for NBS patients is reduced clearage of heavily damaged cells and thus increased oncogenic risk (Porcedda et al., 2006) .
Meiosis and infertility
Ovarian dysgenesis with primary amenorrhea has been described in several NBS patients. DSBs initiate homologous recombination during meiosis; thus it is not unlikely that the observed ovarian dysgenesis is the result of meiotic failure. The hypomorphic mouse models reported so far are discrepant in this respect. In two models, ovaries were degenerated and oogenesis was completely abolished in adult mice (Kang et al., 2002; Difilippantonio et al., 2007) . In contrast, in another mouse model, morphologies of both testes and ovaries in adults were normal. However, more detailed examination of meiosis in female embryos and adult males has revealed incomplete synapsis of homologues during zygotene of spermatogenesis and increased proportions of zygotene phase in both spermatogenesis and oogenesis (Cherry et al., 2007) . Interestingly, the same investigations on mice with hypomorphic MRE11 mutations showed a much stronger effect indicating a disturbance in strand invasion during homologous recombination (Cherry et al., 2007) .
NBS1 in neuronal development
Microcephaly is a cardinal feature of NBS, but is not present in the hypomorphic mouse models so far described. Nevertheless, mutation of genes involved in neural proliferation is expected to give rise to microcephaly (Lian and Sheen, 2006) and indeed, a neurological phenotype in the mouse has been obtained by generating null mutations in NBS1, specifically in developing neurons . These mice have severely disrupted cerebella due to both p53-dependent apoptosis of post-mitotic neurons and proliferative defects in neural stem cells. This pattern is compatible with a role for nibrin in the initiation of DNA repair by both non-homologous end-joining and homologous recombination (Orii et al., 2006) . Accompanying the observed loss of cerebellar structure was severe ataxia, a feature of AT but not of NBS. The fact that NBS patients do not present with more severe disturbances of the central nervous system reflects once again the partial activity of p70-nibrin. Microcephaly has been described as a general feature of defects in the ATR signalling pathway (O'Driscoll et al., 2007) , a pathway in which nibrin is directly involved.
In addition to microcephaly, other neurological features have been described in NBS. In twin boys compound heterozygous for the 657D5 and 643C>T mutations, there was profound microcephaly accompanied by enlarged lateral ventricles and subarachnoidal areas and poor gyrification (Seemanova et al., 2006) , usually indicative of a defect in genes regulating neuron migration (Lian and Sheen, 2006) . Possibly this reflects the compromised proliferation of neurons due to the NBS1 mutations.
NBS1, a haploinsufficient tumor suppressor gene
Nijmegen breakage syndrome patients have an extremely high risk for developing cancer. In our recently published study, 14 of 26 patients investigated had cancer, the majority lymphoma, with a median age at manifestation of 11 years . Considering the characteristic chromosome instability of NBS including chromosome translocations involving the T-cell receptor and immunoglobulin genes, lymphomas in NBS could be expected to arise from cells with aberrations involving these loci. Examination of the humanized mouse model mentioned previously has confirmed this expectation. In these mice, there was a high level of spontaneous translocations in T cells often involving the T-cell receptor loci and, in B-cell and T-cell lymphomas isolated from these mice, complex translocations involving the IgH locus were also found .
The increased cancer incidence in NBS homozygotes was previously suggested to be accompanied by an increased cancer risk for heterozygotes based on the frequency of cancer among relatives of NBS patients (Seemanova, 1990) . This has now been confirmed in a large cohort study of the relatives of 18 NBS patients. Considering just the grandparents, for whom confounders were minimal, in 40 individuals homozygous for the wild-type NBS1 allele, there were three cases of cancer, and in 39 individuals who were heterozygous for the founder mutation 657D5, there were 15 cancers. This equates to a statistically highly significant (P ¼ 0.001) odds ratio of 7.7 for the increased cancer risk in heterozygotes .
Many studies, summarized in Table 1 , have examined cancer patients for germline mutations in NBS1. Clearly, 657D5, the founder mutation, and R215W, a missense mutation, are found considerably more frequently in cancer patients than in controls, supporting the result of the cohort study described above. Unlike NBS homozygotes, the increased cancer risk in heterozygotes is not at all specific for lymphatic malignancy but covers a much wider range of tumor sites.
Although loss of the wild-type NBS1 allele has been reported for some tumors in patients with a germline mutation in one NBS1 allele (Cybulski et al., 2004) , our own results (Varon et al., 2001 and unpublished) suggest that this is probably not the usual mechanism for tumor initiation. Rather, it seems that NBS1 belongs to the group of haploinsufficient tumor suppressor genes, of which some 40, including several genes involved in DNA repair, have been described (reviewed in Santarosa and Ashworth, 2004) . Unlike classical tumor supressor genes in the two-hit model of tumorigenesis, the wild-type alleles of haploinsufficient tumor suppressors are not lost or inactivated in tumors. Rather, tumor development is due solely to the effects of a reduction in gene dosage. Figure 2a illustrates the difference between twohit suppressor genes and haploinsufficient tumor suppressor genes. For comparison, Figure 2b shows cancer incidence for different NBS1 genotypes based on our own published data Seemanova et al., 2006a) . A compromised response to DNA damage leads to an increased mutation rate and accelerated tumor development. In agreement with this, median age at malignancy is indeed reduced as a function of NBS1-copy number (Figure 2c) .
We have previously reported a significantly higher incidence of tumors in mice heterozygous for a null mutation in NBS1. Importantly, in none of the analysed tumors was the wild-type allele lost or inactivated (Dumon-Jones et al., 2003) , again illustrating that reduced gene dosage is sufficient for tumor development. Unlike the mouse model referred to here, the major mutation in NBS patients and heterozygotes produces partially active p70-nibrin (Demuth et al., 2004) . Thus, in terms of protein activity, heterozygotes have actually somewhat more than the theoretically expected 50% based solely on gene copy number.
A dosage effect is probably true for at least one other NBS1 mutation associated with cancer, 643C>T (R215W; Table 1 ). We have previously described twin boys who are compound heterozygotes for 657D5 and 643C>T (Seemanova et al., 2006) . In cells from these children, the only full-length nibrin produced is expressed from the 643C>T allele. Comparing the amount of protein has indicated that it is reduced to 1/3 in comparison with cells heterozygous for the 657D5 mutation. Probably the substitution of tryptophan for arginine has a strong destabilizing effect on the protein and effectively reduces the cellular concentration of functional nibrin. Indeed, activation of ATM was severely compromised in these cells (Seemanova et al., 2006) . Thus, here too, the mechanism of tumorigenesis may be related to NBS1 dosage.
Nibrin is required not only for ATM activation but also for ATR-dependent phosphorylation (Stiff et al., 2005) . The kinase ATR is activated by single-stranded DNA generated during excision repair or at stalled replication forks. It has recently been demonstrated that the ATR signalling pathway is particularly sensitive to haploinsufficiency of genes implicated in its regulation; for example, heterozygous deletion of RPA1 and RFC2 leads to impaired ATR signalling in response to DNA damage (O'Driscoll et al., 2007) . Possibly, the effects of NBS1 haploinsufficiency are due to disturbance of the ATR pathway too.
Increasing evidence suggests that overexpression of nibrin may also contribute to cellular transformation and Abbreviations: ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin's lymphoma.
Defective response to DNA DSBs I Demuth and M Digweed cancer. Increased nibrin expression was observed in 40-52% of various carcinomas examined and the oncogenic nature of nibrin overexpression was demonstrated by injecting nude mice with HeLa cells overexpressing nibrin. These mice developed more and larger tumors than animals injected with untreated HeLa cells . In this connection, it is interesting that overexpression of full-length wild-type nibrin in a cancer cell line resulted in a 30-fold sensitization to IR due, perhaps, to competition with the trimeric M/R/N complex for binding interacting proteins (Rhee et al., 2007) . Since the dosage of nibrin is obviously critical, the question arose of whether constitutive individual variation in the expressed level of p70-nibrin among NBS patients might have a significant impact on cancer incidence. We have addressed this question by exploiting a large collection of lymphoblastoid cell lines from patients with well-documented medical history. Indeed, cancer occurrence was highest in the subgroup of patients whose cell lines had lower than average p70-nibrin expression and lowest in the subgroup of patients with above average p70-nibrin levels . Again, these findings are compatible with a dosage effect in line with the concept of NBS1 as a haploinsufficient tumor suppressor gene.
